Digital Content

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. We’ll assume you’re ok with this, but you can opt out if you wish. See our 

Footer

Column Name Goes Here

Footer V2

2024 Event

Event Global

New HLTH Insights Programs

Become a Hosted Buyer

Become a Sponsor/Exhibitor

Apply for Media Pass

Promote Your Presence

2023 Event

Event Global Footer

Startup Opportunities

Hotel

2022 Event

LLC Global

2021 Event

LLC Menu Official

LLC Menu

How Much of Longevity Is Controllable?—featuring Melanie Goldey

Research has shown that less than 10% of longevity is based on genetics and 90% hinges on your lifestyle choices. But if you don’t have Bryan Johnson’s resources, how do you identify the gap between your chorological age versus your real age? And more importantly, how do you use that information to design a plan that will truly move the needle on helping you live healthier, longer? Melanie Goldey is CEO of <a href="https://tallyhealth.com/" target="_blank">Tally Health</a>, a biotech company developing science-backed tools for consumers to increase health span and extend longevity.  Melanie has an extensive background in technology and healthcare startups, and she is passionate about making longevity science accessible to consumers. On this episode of HLTH Matters, Melanie joins host Dr. Gautam Gulati to discuss the future of diagnostic markers and testing to optimize for the extension of both lifespan and health span. Melanie explains how Tally Health differs from prior iterations of real age measurement and describes how her team uses DNA methylation to develop personalized recommendations for its members. Listen in to understand the benefits of Tally Helth’s pro-longevity supplements and learn how to enhance longevity with small improvements to your diet, fitness, sleep, mental health and habits! Topics Covered<ul><li>How Tally Health is working to help consumers live healthier, longer</li><li>The 3 components of Tally Health’s consumer longevity offering</li><li>What differentiates Tally from prior iterations of real age measurement</li><li>How Tally uses DNA methylation to develop personalized recommendations</li><li>David Sinclair’s research on epigenetics and his information theory of aging</li><li>How much of longevity is based on genetics vs. lifestyle choices</li><li>How Melanie thinks about quick fixes vs. small lifestyle adjustments</li><li>The benefits of Tally Health’s pro-longevity supplements </li><li>How machine learning can improve specificity of Tally’s recommendations</li><li>The connections among diet, fitness, sleep, mental health and habits</li><li>What we might learn from Bryan Johnson’s biohacking experiences</li><li>Other markers Tally Health is studying (beyond DNA methylation)</li></ul>Connect with Melanie Goldey<ul><li><a href="https://tallyhealth.com/" target="_blank">Tally Health</a></li><li>Melanie on <a href="https://www.linkedin.com/in/melanie-goldey/" target="_blank">LinkedIn</a></li></ul>Connect with Dr. Jessica Shepherd &amp; Dr. Gautam Gulati<ul><li><a href="https://www.hlth.com/" target="_blank">HLTH</a></li><li>Dr. Shepherd on <a href="https://twitter.com/JShepherd_MD" target="_blank">X</a></li><li>Dr. Shepherd on <a href="https://www.linkedin.com/in/jessica-shepherd-md-mba-5ba9ab66/" target="_blank">LinkedIn</a></li><li>Dr. Gulati on <a href="https://twitter.com/drgautamgulati" target="_blank">X</a></li><li>Dr. Gulati on <a href="https://www.linkedin.com/in/gautamgulati/" target="_blank">LinkedIn</a></li></ul>Resources<ul><li><a href="http://www.hms.harvard.edu/agingresearch/" target="_blank">Harvard Aging Lab</a></li><li><a href="https://www.nature.com/articles/s41586-020-2975-4" target="_blank">David Sinclair’s Landmark Study on Longevity in Nature</a></li><li><a href="https://www.bryanjohnson.com/" target="_blank">Bryan Johnson</a></li></ul>

S4 E42: How Much of Longevity Is Controllable?—featuring Melanie Goldey

The Beat: The Future of Virtual Care

How does Teladoc manage the equilibrium between revenue growth and profitability, and what approaches are they employing to enhance value for their customers? In this episode, Kelly Bliss, President of U.S. Group Health at Teladoc, delves into Teladoc&#39;s significant growth agenda, focusing on areas such as whole-person health and the innovative strategies they are employing in the telehealth industry. Kelly shares insights into their balanced growth approach, investment in research and development, and the value they offer to clients. She also covers the forecast for virtual care spending, the impact of AI on revenue and cost management, and Teladoc&#39;s innovative weight loss program.  Tune in for a deep dive into the evolving landscape of virtual health services and the innovative strategies driving Teladoc&#39;s growth. About Kelly Bliss:Kelly Bliss is president of U.S. Group Health. She oversees sales, client management, and client and commercial operations for the business. Ms. Bliss has strong expertise in creating cohesive client-focused organizations. Most recently, she held the position of chief client officer at Teladoc Health. Under her leadership, client services achieved record growth and retention through a focus on delivering value and a best-in-class experience to our clients. Ms. Bliss also built and managed high-functioning, global teams at companies such as Best Doctors and InterSystems. At Best Doctors, she served as chief of staff, leading the organization&#39;s key strategic growth initiatives until the eventual acquisition by Teladoc Health in 2017. Ms. Bliss was recognized as one of the Top 25 Women Leaders in Healthcare Software of 2020 by The Healthcare Technology Report and serves as executive sponsor for the Teladoc Health Women&#39;s Network. She holds a bachelor&#39;s degree in industrial psychology from Nichols College. Things You’ll Learn:<ul><li>Teladoc places a priority on well-rounded growth, giving significant attention to both revenue and profitability. </li><li>This commitment is supported by a robust balance sheet and substantial investments in research and development.</li><li>The growing significance of hyper-personalized member experiences and the utilization of multiple artificial intelligence models to enhance outcomes for clients and members.</li><li>Kelly Bliss&#39;s professional odyssey as a &quot;code breaker&quot; involves challenging norms and assembling unconventional teams to optimize and create high-performance team dynamics.</li><li>The surge of virtual care is evident, with Teladoc&#39;s research indicating a growing trend among employers investing in comprehensive virtual care providers. </li></ul>Resources:<ul><li>Connect with and follow Kelly Bliss on <a href="https://www.linkedin.com/in/kellybliss/" target="_blank">LinkedIn</a>.</li><li>Follow Teladoc on <a href="https://www.linkedin.com/company/teladoc-health/" target="_blank">LinkedIn</a> and visit their <a href="https://www.teladochealth.com/" target="_blank">website</a>.</li></ul>

S1 E11: The Beat: The Future of Virtual Care

President, US Group Health

Your Health Insurer Doesn’t Want You To Listen To This: Interview with Curative

While many insurance plans include preventive care, Curative’s distinctive feature is providing 100% coverage for all in-network care to actively promote prevention. In this episode, Fred Turner, CEO of Curative, shares insights into the dire need for transformation in employer-sponsored health insurance, addressing the issues faced by both employees and employers. He discusses the company&#39;s unique model that focuses on providing preventative care with zero out-of-pocket costs for members during the first 120 days. Fred also emphasizes the importance of simplifying the healthcare system and highlights the positive impact Curative&#39;s approach has on both employees and employers. Fred sheds light on the skepticism and reluctance of employers to adopt new health plans but emphasizes the significant impact experienced by those who embraced Curative&#39;s approach.  Tune in to learn more about the inspiring work Fred and his team are doing to revolutionize healthcare and improve access to quality care. About Fred Turner:Fred Turner is the Chief Executive Officer and co-founder of Curative. A British scientist from West Yorkshire, Turner attended the University of Oxford. Turner was named one of the top 100 practicing scientists in the UK by the Science Council in 2013. He was also included in Forbes’ ‘30 Under 30’ list and ranked first in the European Union Contest for Young Scientists. Recently, Fred was awarded Comparably&#39;s Best CEO Award and Modern Healthcare’s Top 25 Emerging Leaders in 2021. Under Turner’s leadership, Curative launched a first-of-its-kind health insurance plan that offers unmatched transparency into healthcare costs. Inspired by his vision to create a healthcare system that works for and supports patients’ whole health through every step of their personal health journey, Turner and the Curative team developed a path-breaking health plan with no copays, no deductibles, and no cost-sharing for its members. Previously, Turner led Curative as it became the national leader in bringing COVID-19 testing and vaccine administration resources to people in response to the pandemic, having provided more than 36 million tests and two million vaccines across thousands of locations in more than 40 states. Prior to creating both of Curative’s highly innovative business models, Fred founded and led a 16z and YC-backed diagnostics (Dx) startup that built a CLIA lab for validating and launching an STD testing product in Menlo Park, California. Things You’ll Learn:<ul><li>High Deductible Health Plans (HDHP) are leaving insured individuals functionally uninsured, unable to afford out-of-pocket costs for care.</li><li>Curative&#39;s unique model offers 120 days of no out-of-pocket cost for in-network care, promoting preventative care and simplifying health benefits.</li><li>Employers experiencing rising insurance costs can benefit from exploring new options like those offered by Curative to better support their employees&#39; health and well-being.</li><li>The importance of making healthcare access and benefits clear and straightforward. </li><li>Curative’s approach yields an impressive 98% member engagement rate, demonstrating the effectiveness of its model in promoting proactive health management.</li></ul> Resources:<ul><li>Connect with and follow Fred Turner on <a href="https://www.linkedin.com/in/fred-turner/" target="_blank">LinkedIn</a>.</li><li>Follow Curative on <a href="https://www.linkedin.com/company/curativeinc/" target="_blank">LinkedIn</a> and visit their <a href="https://curative.com/" target="_blank">website</a>.</li></ul>

S4 E18: Your Health Insurer Doesn’t Want You To Listen To This: Interview with Curative CEO & co-founder Fred Turner

Chief Executive Officer

A New Dawn in Early Cancer Detection with Dr. Megan Hall of GRAIL

In this groundbreaking era of healthcare, the opportunity to revolutionize cancer outcomes has never been more promising. With cutting-edge testing techniques, early detection strategies, and the power of AI, the landscape of cancer care is evolving to save lives and enhance patient well-being like never before. In this episode of HLTH Matters, Dr. Gautam Gulati sits down with Dr. Megan Hall to discuss the future of cancer detection and prevention through early genetic testing.  <a href="https://www.linkedin.com/in/megan-p-hall-2401068/" target="_blank">Dr. Megan Hall</a> is the Vice President of Corporate Affairs at <a href="https://grail.com/" target="_blank">GRAIL</a>. With a Ph.D. in microbiology, immunology, and molecular genetics she is dedicated to making early cancer detection and prevention accessible on a population scale. As Dr. Hall says, “I was enamored of the mission to detect cancer early when it can be cured. That&#39;s a huge problem that we have to be frank have not made great headway on in the 50 years that we&#39;ve been waging this war on cancer.”  Now she shares how GRAIL&#39;s flagship product, <a href="https://grail.com/galleri-test/" target="_blank">Galleri</a>, is using advanced technology, including DNA methylation analysis and artificial intelligence (AI), to detect and predict cancer in a non-invasive way.  Listen in as we explore the potential cost savings and improved outcomes with early cancer detection, and GRAIL&#39;s efforts to make this transformative technology accessible to a broader population.  Topics Covered<ul><li>The significance of early detection in cancer care</li><li>The role of DNA methylation in cancer detection</li><li>The importance of evaluating the accuracy of cancer screening and the power of positive predictive value</li><li>The need for education across the cancer care continuum</li><li>The potential for healthcare cost savings with early cancer detection</li><li>The role of AI and machine learning in cancer detection</li><li>GRAIL&#39;s focus on expanding access to cancer screening and its plans for future products</li></ul>Connect with Dr. Megan Hall<ul><li>Dr. Hall on <a href="https://www.linkedin.com/in/megan-p-hall-2401068/" target="_blank">LinkedIn</a> </li></ul>Connect with Dr. Gautam Gulati &amp; Dr. Jessica Shepherd <ul><li><a href="https://www.hlth.com/" target="_blank">HLTH</a></li><li>Dr. Gulati on <a href="https://twitter.com/drgautamgulati" target="_blank">X</a> </li><li>Dr. Gulati on <a href="https://www.linkedin.com/in/gautamgulati" target="_blank">LinkedIn</a></li><li><a href="https://www.drjessicashepherd.com/about" target="_blank">Dr. Jessica Shepherd MD </a></li><li>Dr. Shepherd on <a href="https://twitter.com/JShepherd_MD" target="_blank">X</a> </li></ul>Resources <ul><li><a href="https://grail.com/" target="_blank">GRAIL</a> </li><li><a href="https://grail.com/galleri-test/" target="_blank">Galleri Test - GRAIL </a></li></ul>

S4 E41: A New Dawn in Early Cancer Detection with Dr. Megan Hall of GRAIL

Head of Corporate Affairs, Distinguished Scientist

Podcast

S4 E42: How Much of Longevity Is Controllable?—featuring Melanie Goldey

FEATURING